Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies

AbstractThe potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on COVID-19 vaccination is poorly understood. According to recent observations, the humoral immune response could be impaired in patients treated with ocrelizumab or fingolimod. Our study evaluated the immunogenicity and safety of mRNA COVID-19 vaccines in a convenience sample of 140 MS patients treated with different DMTs, undergoing vaccination between April and June 2021. Humoral immune response was tested 1  month after the second dose, using a chemiluminescent microparticle immunoassay to detect IgG against SARS-CoV-2 nucleoprotein. We explored the potential correlation between the IgG titer and DMTs. All patients in treatment with first-line DMTs, natalizumab, cladribine, and alemtuzumab, developed a measurable humoral response. In patients treated with ocrelizumab and fingolimod, the IgG level was significantly lower, but only some patients (22.2% for fingolimod and 66% for ocrelizumab) failed to develop a measurable humoral response. In the ocrelizumab group, the IgG level was positively cor related with the time from last infusion. No SARS-CoV-2 infections were reported after vaccination. The most reported side effects were pain at the injection site (57.1%) and fatigue (37.9%). No patient experienced severe side effects requiring hospitalization. Our study confirms that COVID-19 vacci nation is safe and well-tolerated in MS patients and should be recommended to all pa...
Source: Neurotherapeutics - Category: Neurology Source Type: research

Related Links:

CONCLUSION: In our sample, percentages of variation in PLR and PD were found to be directly representative of TBI patients’ fentanyl blood concentration. Considering information about blood drug concentration is generally not available at bedside, PLR could be used as a proxy to assess analgesia requirements before a nociceptive procedure in critically ill sedated TBI patients who are vulnerable to stress.
Source: Journal of Neuroscience Nursing - Category: Neuroscience Tags: Articles Source Type: research
CONCLUSION: It is crucial to consider the classifications of MS and its pathophysiology to determine which medication produces the best results. Our proposed mnemonic can support a clinician's recall ability and assist in identifying the respective MS medication.
Source: Journal of Neuroscience Nursing - Category: Neuroscience Tags: Articles Source Type: research
Cases seem to be subsiding in states with high vaccination rates, but observers are reluctant to make firm predictionsIn February 2021, Dr Craig Spencer wrote in a Mediumpost that he was as “eager as anyone to see the end of this pandemic. Thankfully, that may be in sight”.“Covid cases and hospitalizations are dropping,” wrote Spencer, director of Global Health in Emergency Medicine at New York-Presbyterian/Columbia University Medical Center. “Vaccines are getting into arms. So, what happens next?”Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Omicron variant Coronavirus Science New York US news North Carolina Source Type: news
Here's how this reaction may be different from an immediate skin reaction.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma Source Type: news
The stunning Covid vaccines manufactured by Pfizer-BioNTech and Moderna drew upon long-buried discoveries made in the hopes of ending past epidemics.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Clinical Trials Coronavirus (2019-nCoV) Vaccination and Immunization National Institutes of Health MERS (Middle East Respiratory Syndrome) Acquired Immune Deficiency Syndrome Graham, Barney S (1953- ) Kariko, Katalin (1955- ) Fauci, Anthon Source Type: news
In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for […]
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology antiviral coronavirus COVID-19 delta inflammation Long Covid monoclonal antibody pandemic SARS-CoV-2 vaccine vaccine booster variant of concern viruses Source Type: blogs
AbstractThe potential impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on COVID-19 vaccination is poorly understood. According to recent observations, the humoral immune response could be impaired in patients treated with ocrelizumab or fingolimod. Our study evaluated the immunogenicity and safety of mRNA COVID-19 vaccines in a convenience sample of 140 MS patients treated with different DMTs, undergoing vaccination between April and June 2021. Humoral immune response was tested 1  month after the second dose, using a chemiluminescent microparticle immunoassay to detect IgG against SARS-CoV-2 n...
Source: Neurotherapeutics - Category: Neurology Source Type: research
The objective of this retrospective cross-sectional study was to generate real-world multiple sclerosis–specific vaccine safety information, particularly in the context of specific DMTs, and provide information to mitigate specific concerns in vaccine hesitant PwMS. Methods Between 3/2021 and 6/2021, participants in iConquerMS, an online people-powered research network, reported SARS-CoV-2 vaccines, experiences of local (itch, pain, redness, swelling, or warmth at injection site) and systemic (fever, chills, fatigue, headache, joint pain, malaise, muscle ache, nausea, allergic, and other) reactions within 24 hours (...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Public health, Multiple sclerosis, All epidemiology Article Source Type: research
CONCLUSION: Although it is a sporadic finding, SARS-CoV-2 can cause transverse myelitis. The condition responds to medical therapy.PMID:34457267 | PMC:PMC8380545 | DOI:10.1016/j.amsu.2021.102749
Source: Annals of Medicine - Category: Internal Medicine Authors: Source Type: research
In conclusion, the study indicates that HBOT may induce significant senolytic effects that include significantly increasing telomere length and clearance of senescent cells in the aging populations. Data on the Prevalence of Liver Fibrosis in Middle Age https://www.fightaging.org/archives/2020/11/data-on-the-prevalence-of-liver-fibrosis-in-middle-age/ Fibrosis is a consequence of age-related disarray in tissue maintenance processes, leading to the deposition of scar-like collagen that disrupts tissue structure and function. It is an ultimately fatal issue for which there are only poor treatment options a...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Brain | Chemistry | COVID-19 | Gilenya | Multiple Sclerosis | Neurology | Pain | SARS | Study | Tysabri | Vaccines